Cleary’s Pharma Bites: Life Science Sector and International Arbitration: Risks and Opportunities

Cleary Gottlieb’s Pharmaceutical, Biotech, and Healthcare group is pleased to present the latest installment of its “Pharma Bites” series: Life Science Sector and International Arbitration: Risks and Opportunities.

Why Arbitration?

• Efficiency and neutrality of international arbitration, as a single forum.
• Expertise of international arbitrators.
• Other typical advantages of international arbitration: greater ease of enforcement of arbitral awards; confidentiality of the proceedings; procedural flexibility; specific regime for emergency relief.

To learn more about this topic and view the related slide deck, click here.

Cleary’s Pharma Bites series seeks to provide critical updates on a wide range of antitrust, regulatory, arbitration, and litigation issues in the pharmaceutical and biotechnology space. 

To learn more about Cleary’s Pharmaceuticals and Biotechnology practice, click here.